Monthly Prescribing Reference

FDA Approves Definity Labeling Removing Contraindication

Lantheus Medical Imaging announced that the Food and Drug Administration (FDA) has approved a label update for Definity (perflutren lipid microsphere) injectable suspension with the removal of a ...
Business Wire

Lantheus Medical Imaging Announces FDA Approval of DEFINITY ® Label Update

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc. (“Lantheus”) today announced U.S. Food and Drug Administration (FDA) approval of an important label update for DEFINITY ® Vial ...
Medscape

FDA Backpedals on Warnings in Echo-Contrast Labeling

May 13, 2008 - The US FDA has approved less ominous and restrictive language for the labeling of the echocardiographic contrast agents perflutren lipid microspheres injectable suspension (Definity, ...
Nasdaq

Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...